BlueRock Therapeutics: Sizing Up The Regenerative Power Of Cells
An Interview With CEO Emile Nuwaysir
Executive Summary
Bayer's novel 2016 joint venture with the venture capital group Versant Ventures has spawned something like a big pharma, new science start-up, with an open mandate to disrupt drug development through generous endowments in the scarce commodities of freedom, time and patience.